3-(difluoromethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine | 1220696-58-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(difluoromethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
• 英文别名: (5-(difluoromethyl)pyridin-3-yl)boronic ester
• CAS: 1220696-58-1
• 化学式: C₁₂H₁₆BF₂NO₂
• mdl: MFCD18733447
• 分子量: 255.072
• InChiKey: RDERAJSLRZKDAV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.75
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.583
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(difluoromethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 、 8-bromo-1-(cyclohex-1-en-1-yl)[1,2,4]triazolo[4,3-a]quinoxaline 在 XPhos Pd G2 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 16.0h， 以20 mg的产率得到1-(cyclohex-1-en-1-yl)-8-[5-(difluoromethyl)pyridin-3-yl][1,2,4]triazolo[4,3-a]quinoxaline
  参考文献：
  名称：

  BAY-8400：一种新型强效选择性 DNA-PK 抑制剂，在与靶向 Alpha 疗法联合使用时表现出协同作用

  摘要：

  真核生物已经进化出两种主要途径来修复潜在的致命 DNA 双链断裂。同源重组代表了在 S 和 G2 细胞周期阶段可用的基于 DNA 模板的精确机制，而需要 DNA 依赖性蛋白激酶 (DNA-PK) 的非同源末端连接允许快速、细胞周期独立但不太准确的 DNA 修复。在这里，我们报告了BAY-8400的发现，这是一种新型的 DNA-PK 选择性抑制剂。从三唑并喹喔啉开始，该药物已被确定为共济失调毛细血管扩张症和 Rad3 相关蛋白 (ATR) 抑制剂的筛选结果，该抑制剂对 ATR、ATM 和 DNA-PK 具有抑制活性，主要针对效力和选择性的优化工作导致BAY-8400的发现。在体外研究表明，BAY-8400显示出 DNA-PK 抑制与 DNA 损伤诱导靶向 α 疗法的协同活性。与 PSMA 靶向钍 227 偶联物单一疗法相比，PSMA 靶向钍 227 偶联物 BAY 2315497 与BAY-

  DOI：

  10.1021/acs.jmedchem.1c00762
• 作为产物：
  描述：

  5-溴吡啶-3-甲醛 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 二乙胺基三氟化硫 、 potassium acetate 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 6.0h， 生成 3-(difluoromethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
  参考文献：
  名称：

  Compounds and their use as BACE Inhibitors

  摘要：

  本发明涉及式(I)的化合物及其药物组合物。此外，本发明涉及治疗方法，用于治疗和/或预防与Aβ相关的病理，如唐氏综合症，β-淀粉样蛋白血管病，如但不限于脑淀粉样蛋白血管病或遗传性脑出血，与认知损害相关的疾病，如但不限于MCI（“轻度认知损害”），阿尔茨海默病，记忆丧失，与阿尔茨海默病相关的注意力缺陷症状，与疾病如阿尔茨海默病或痴呆症相关的神经退行性疾病，包括混合性血管性和退行性起源的痴呆，早老性痴呆，老年性痴呆和与帕金森病、进行性上核性麻痹或皮层基底节变性相关的痴呆。

  公开号：

  US20120165347A1

文献信息

• Compounds and their use as BACE inhibitors
  申请人：Astrazeneca AB

  公开号：US08865911B2

  公开（公告）日：2014-10-21

  The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

  本发明涉及式（I）化合物及其药物组合物。此外，本发明涉及治疗和/或预防与Aβ相关的病理状况，如唐氏综合症、β-淀粉样物质血管病，如但不限于脑淀粉样物质血管病或遗传性脑出血，与认知障碍相关的疾病，如但不限于轻度认知障碍（MCI）、阿尔茨海默病、记忆力下降、与阿尔茨海默病相关的注意力缺陷症状，与疾病相关的神经退行性疾病，如阿尔茨海默病或痴呆症，包括混合血管性和退行性起源的痴呆、早老性痴呆、老年性痴呆和与帕金森病、进行性核上性麻痹或皮质基底节变性相关的痴呆的治疗方法。
• COMPOUNDS AND THEIR USE AS BACE INHIBITORS
  申请人：ASTRAZENECA AB

  公开号：US20150133471A1

  公开（公告）日：2015-05-14

  The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

  本发明涉及公式（I）的化合物及其制药组合物。此外，本发明还涉及治疗和/或预防与Aβ相关的病理学，如唐氏综合症，β-淀粉样蛋白血管病，如但不限于脑淀粉样血管病或遗传性脑出血，与认知障碍相关的疾病，如但不限于轻度认知障碍（MCI），阿尔茨海默病，记忆丧失，与阿尔茨海默病相关的注意力缺陷症状，与疾病相关的神经退行性疾病，如阿尔茨海默病或痴呆症，包括混合血管性和退行性起源的痴呆，早老性痴呆，老年性痴呆和与帕金森病，进行性核上性麻痹或皮层基底节变性相关的痴呆。
• Compounds and Their Use as BACE Inhibitors
  申请人：Csjernyik Gabor

  公开号：US20130210837A1

  公开（公告）日：2013-08-15

  The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

  本发明涉及式（I）的化合物及其制药组合物。此外，本发明涉及治疗和/或预防与Aβ相关的病理学，例如唐氏综合症，β-淀粉样蛋白血管病（例如脑淀粉样血管病或遗传性脑出血），与认知损害相关的疾病（例如轻度认知障碍），阿尔茨海默病，记忆力丧失，与阿尔茨海默病相关的注意力缺陷症状，与阿尔茨海默病或痴呆症相关的神经退行性疾病，包括混合性血管性和退行性起源的痴呆，老年前期痴呆，老年痴呆和与帕金森病，进行性核上性麻痹或皮质基底节变性相关的痴呆。
• PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS
  申请人：ALMIRALL, S.A.

  公开号：US20150291595A1

  公开（公告）日：2015-10-15

  New pyrrolotriazinone derivatives having the chemical structure of Formula (I) are disclosed; as well as process for theft preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks).

  本发明揭示了具有化学结构式（I）的新吡咯三唑酮衍生物；以及其制备过程，包括它们的药物组合物和它们作为磷脂酰肌醇3-激酶（PI3Ks）抑制剂在治疗中的用途。
• Pyrrolotriazinone derivatives as PI3K inhibitors
  申请人：ALMIRALL, S.A.

  公开号：US09388189B2

  公开（公告）日：2016-07-12

  New pyrrolotriazinone derivatives having the chemical structure of Formula (I) are disclosed; as well as process for theft preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks).

  本发明揭示了具有化学结构式（I）的新吡咯三嗪衍生物；以及制备它们的方法，包括含有它们的制药组合物和它们作为磷脂酰肌醇3-激酶（PI3Ks）抑制剂在治疗中的用途。